Table G-42Sertraline compared with citalopram: Head-to-head trials

Domains Pertaining to Strength of EvidenceMagnitude of EffectStrength of Evidence
Number of Studies; Number of SubjectsRisk of Bias; DesignConsistencyDirectnessPrecisionSummary Effect Size (95% CI)aHigh, Moderate, Low, Insufficient
PTSD Symptom Reduction: CAPS, mean change from baseline
1; 58Medium; RCTNA, single studyDirectImpreciseS vs. C vs. P: −41.8 vs. −30.7 vs. −38.7, p=NSInsufficient
PTSD Symptom Reduction: IES, mean change from baseline
1; 58Medium; RCTNA, single studyDirectImprecise−29.1 vs. −19.3 vs. −33.2, p=NSInsufficient
Remission (no longer having symptoms)
0; 0NANANANANAInsufficient
Loss of Diagnosis
0; 0NANANANANAInsufficient
Prevention/reduction of comorbid depression: BDI
1; 58Medium; RCTNA, single studyDirectImprecise−13.4 vs. −16.1 vs. −15.6, p=NRInsufficient
Prevention/reduction of comorbid anxiety
0; 0NANANANANAInsufficient
Quality of Life: Q-LES-Q, mean change
0; 0NANANANANAInsufficient
Disability/functional impairment: SDS
0; 0NANANANANAInsufficient
Return to work or return to active duty
0; 0NANANANANAInsufficient
a

Data are from 1 RCT comparing sertraline, citalopram, and placebo.18

Abbreviations: C = citalopram; CI = confidence interval; NA = not applicable; NR = not reported; p=placebo; RCT = randomized controlled trial; S = sertraline

From: Appendix G, Strength of Evidence

Cover of Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder (PTSD)
Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder (PTSD) [Internet].
Comparative Effectiveness Reviews, No. 92.
Jonas DE, Cusack K, Forneris CA, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.